Antimalarial drug development and new targets

Parasitology Today

Volumn 16, Issue 10, 2000, Pages 438-444

  Macreadie, I ^a   Ginsburg, H ^b   Sirawaraporn, W ^c   Tilley, L ^d  

^a CSIRO   (Australia)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c MAHIDOL UNIVERSITY   (Thailand)

^d LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; CHLOROQUINE; CYCLOGUANIL; FOLIC ACID; FOLIC ACID ANTAGONIST; HALOFANTRINE; MEFLOQUINE; NATURAL PRODUCT; PYRIMETHAMINE; PYRIMIDINE; QUININE; QUINOLINE; UBIQUINONE;

ANTIMALARIAL ACTIVITY; CHEMOTHERAPY; GENOME; MALARIA; MEROZOITE; NONHUMAN; PLASMODIUM; REVIEW; TECHNOLOGY;

ANIMALS; ANTIMALARIALS; DRUG DESIGN; DRUG RESISTANCE; FOLIC ACID ANTAGONISTS; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 0034307631     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(00)01758-0     Document Type: Review

References (54)

1. Olliaro P., Yuthavong Y. An overview of chemotherapeutic targets for antimalarial drug discovery. Pharmacol. Ther. 81:1999;91-110.
2. Winstanley P.A. Chemotherapy for falciparum malaria. the armoury, the problems and the prospects Parasitol. Today. 16:2000;146-153.
3. Sirawaraporn W. Dihydrofolate reductase and antifolate resistance in malaria. Georgopapadakou N. Drug Resistance Update Vol. 1. 1998;397-406 Churchill Livingstone.
4. Sirawaraporn W.et al. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1124-1129.
5. McKie J.H.et al. Rational drug design approach for overcoming drug resistance. application to pyrimethamine resistance in malaria J. Med. Chem. 41:1998;1367-1370.
6. Walker-Jonah A.et al. An RFLP map of the Plasmodium falciparum genome, recombination rates and favored linkage groups in a genetic cross. Mol. Biochem. Parasitol. 51:1992;313-320.
7. Wang P.et al. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol. Microbiol. 32:1999;1254-1262.
8. Wang P.et al. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol. Microbiol. 23:1997;979-986.
9. Su X.et al. A genetic map and recombination parameters of the human malaria parasite Plasmodium falciparum. Science. 286:1999;1351-1353.
10. Wooden J.M.et al. Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol. Biochem. Parasitol. 85:1997;25-40.
11. Sibley C.H.et al. Yeast as a model system to study drugs effective against apicomplexan proteins. Methods. 13:1997;190-207.
12. Foley M., Tilley L. Quinoline antimalarials. mechanisms of action and resistance and prospects for new agents Pharmacol. Ther. 79:1998;55-87.
13. O'Neill P.M.et al. 4-Aminoquinolines-past, present, and future. a chemical perspective Pharmacol. Ther. 77:1998;29-58.
14. Ginsburg H.et al. An integrated model of chloroquine action. Parasitol. Today. 15:1999;357-360.
15. Yayon A.et al. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 3:1984;2695-2700.
16. Chou A.C.et al. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry. 19:1980;1543-1549.
17. Bray P.G.et al. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J. Cell Biol. 145:1999;363-376.
18. Bray P.G.et al. Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. A correlation of chloroquine sensitivity with energy-dependent drug accumulation. Biochem. Pharmacol. 44:1992;1317-1324.
19. Krogstad D.J.et al. Energy dependence of chloroquine accumulation and chloroquine efflux in Plasmodium falciparum. Biochem. Pharmacol. 43:1992;57-62.
20. Yayon A.et al. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc. Natl. Acad. Sci. U.S.A. 82:1985;2784-2788.
21. Bray P.G.et al. Vacuolar acidification and chloroquine sensitivity in Plasmodium falciparum. Biochem. Pharmacol. 43:1992;1219-1227.
22. Dorn A.et al. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem. Pharmacol. 55:1998;727-736.
23. Egan T.J.et al. Characterisation of synthetic beta-haematin and effects of the antimalarial drugs quinidine, halofantrine, desbutylhalofantrine and mefloquine on its formation. J. Inorg. Biochem. 73:1999;101-107.
24. Vippagunta S.R.et al. Structural specificity of chloroquine-hematin binding related to inhibition of hematin polymerisation and parasite growth. J. Med. Chem. 42:1999;4630-4639.
25. Slater A.F.G., Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 355:1992;167-169.
26. Ginsburg H.et al. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem. Pharmacol. 56:1998;1305-1313.
27. Loria P.et al. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem. J. 339:1999;363-370.
28. Sugioka Y., Suzuki M. The chemical basis for the ferriprotoporphyrin IX-chloroquine complex induced lipid peroxidation. Biochim. Biophys. Acta. 1074:1991;19-24.
29. Pandey A.V.et al. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J. Biol. Chem. 274:1999;19383-19388.
30. Su X.et al. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell. 91:1997;593-603.
31. Reed M.B.et al. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 403:2000;906-909.
32. Wellems T.E.et al. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature. 345:1990;253-255.
33. Kirk K.et al. Transport of diverse substrates into malaria-infected erythrocytes via a pathway showing functional characteristics of a chloride channel. J. Biol. Chem. 269:1994;3339-3347.
34. +-ATPase. J. Biol. Chem. 274:1999;33213-33219.
35. + antiport of Plasmodium falciparum membrane. J. Cell Physiol. 154:1993;527-534.
36. Ginsburg H. The permeability properties of the parasite cell membrane. Novartis Foundation. Symposium. 226:1999;99-108.
37. +)-ATPase. Annu. Rev. Dev. Biol. 13:1997;779-808.
38. Karcz S.R.et al. Cloning and characterization of the vacuolar ATPase B subunit from Plasmodium falciparum. Mol. Biochem. Parasitol. 65:1994;123-133.
39. Karcz S.R.et al. Cloning and characterization of a vacuolar ATPase-A subunit homologue from Plasmodium falciparum. Mol. Biochem. Parasitol. 58:1993;333-344.
40. Desai S.A.et al. A nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature. 362:1993;643-646.
41. + transport in Plasmodium falciparum-infected red cells. J. Membr. Biol. 172:1999;13-24.
42. Brown D.M.et al. L-nucleoside analogues as potential antimalarials that selectively target Plasmodium falciparum adenosine deaminase. Nucleosides Nucleotides. 18:1999;2521-2532.
43. Gero A.M., O'Sullivan W.J. Purines and pyrimidines in malarial parasites. Blood Cells. 16:1990;467-484.
44. McFadden G.I.et al. Plastid in human parasites. Nature. 381:1996;482.
45. Wilson R.J.et al. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 261:1996;155-172.
46. Kohler S.et al. A plastid of probable green algal origin in apicomplexan parasites. Science. 275:1997;1485-1489.
47. Waller R.F.et al. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 95:1998;12352-12357.
48. Clough B.et al. Antibiotic inhibitors of organellar protein synthesis in Plasmodium falciparum. Protist. 150:1999;189-195.
49. Wilson R.J.et al. Malaria and other apicomplexans. the 'plant' connection Infect. Agents Dis. 3:1994;29-37.
50. McFadden G.I., Roos D.S. Apicomplexan plastids as drug targets. Trends Microbiol. 7:1999;328-333.
51. Dluzewski A.R.et al. Invasion of hereditary ovalocytes by Plasmodium falciparum in vitro and its relation to intracellular ATP concentration. Mol. Biochem. Parasitol. 55:1992;1-7.
52. Li R.et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. Mol. Biol. 295:2000;307-323.
53. Müller S.et al. In the human malaria parasite Plasmodium falciparum, polyamines are synthesized by a bifunctional ornithine decarboxylase, S-adenosylmethionine decarboxylase. J. Biol. Chem. 275:2000;8097-8102.
54. Marton L.J., Pegg A.E. Polyamines as targets for therapeutic intervention. Annu. Rev. Pharmacol. Toxicol. 35:1995;55-91.